Anne Wyllie

Last updated

Anne Wyllie
Anne Wyllie, scientist from New Zealand (cropped).png
Wyllie in 2021
Born
Anne Louise Wyllie

1985
Auckland, New Zealand
Nationality New Zealander
Other namesThe Spit Queen [1]
Alma mater University of Auckland
Utrecht University
Known forDeveloping saliva testing for SARS-CoV-2
AwardsCOVID-19 Research Award (Yale School of Public Health)
Scientific career
FieldsEpidemiology of microbial diseases
InstitutionsPublic Health Modeling Unit, Yale University
Thesis Molecular surveillance of pneumococcal carriage in all ages  (2016)
Doctoral advisor Elisabeth Sanders
Krzystof Trzcinski

Anne Louise Wyllie (born 1985) is a New Zealand microbiologist who was the lead author of a 2020 research article which led to the development of the SalivaDirect PCR method of testing saliva for SARS-CoV-2, the virus that causes COVID-19. [2] She has also worked on community studies to better understand pneumococcal disease. [3] She is a research scientist in epidemiology with the Public Health Modeling Unit at Yale University.

Contents

Early life and education

Wyllie studied at Northcote College in Auckland. She completed a BSc in Biomedical Science at the University of Auckland in 2007, followed by a Postgraduate Diploma, [4] and Masters in Medical Science in 2009 at the Auckland Cancer Society Research Centre (University of Auckland), with a dissertation entitled In vitro studies of the anti-tumour agent DMXAA. [5] Wyllie completed a PhD in medical microbiology in 2016 at Utrecht University, with a dissertation entitled Molecular surveillance of pneumococcal carriage in all ages. [6] [7] Since early 2020, she has worked as a research scientist in the Department of Epidemiology of Microbial Diseases at the Yale School of Public Health at Yale University. [7]

Saliva testing research

Wyllie began working on the use of saliva as a sample source to improve the detection of the pneumococcus bacteria in community settings in 2011. [6] [8]

In early 2020, at the start of the COVID-19 pandemic, Wyllie joined the Yale IMPACT Covid responses where they encountered a collapse of the supply chain for nasopharyngeal swabs, as well as hesitancy by both patients and healthcare staff to perform swabbing. This prompted her to advocate the validation of saliva testing for SARS-CoV-2. [9] Wyllie wanted to develop a saliva test for SARS-CoV-2 but was hampered by a lack of funding. [10]

By April 2020, Wyllie and her colleagues had demonstrated that saliva could be a sensitive and reliable sample for SARS-CoV-2 detection. Wyllie and her team compared side-by-side samples of "gold standard" nasopharyngeal swabs and saliva samples. They discovered that saliva samples could be just as reliable. [11] They also found asymptomatic individuals were testing positive in saliva samples several days before the nasopharyngeal swabs would be positive; however, Wyllie wanted to further develop saliva as a sample type to enable frequent, repeat testing and to drive down testing costs to make testing more accessible. During the spring of 2020, Wyllie and others in Nathan Grubaugh's lab developed a test called SalivaDirect, described as simpler, cheaper, and less invasive than nasopharyngeal testing. The SalivaDirect test collects saliva in a tube without requiring a swab and thus does not require collection by healthcare workers. It also does not involve RNA extraction, allowing direct PCR testing of samples, and cutting the time required to process samples as well as the expense of testing. Removing the RNA extraction from the process also allows a wider range of laboratories to engage in saliva testing than nasopharyngeal testing. [10] [11]

In April 2020, Wyllie, as lead author, submitted a paper to The New England Journal of Medicine describing the team's research; it was published in August 2020. [2]

This work sparked interest from the NBA which was keen to pursue saliva-testing as a means to run a season more safely. Funding from the NBA supported the development, validation, and optimization of SalivaDirect while providing a test population to validate the test for use in asymptomatic people. The SalivaDirect test received FDA emergency use authorization in August 2020, allowing for its nationwide rollout. Through the Fast Grant, part of the Emergent Ventures scheme set up by economist Tyler Cowen, she was able to raise an additional $500,000 to support the further development of the test and to support local testing efforts. For her efforts, Wyllie was dubbed the "Spit Queen" in an interview on NPR. [10]

In August 2021, Wyllie wrote to New Zealand prime minister Jacinda Ardern to express her concerns over the slow rollout of saliva testing in New Zealand, when other countries had been saliva-testing widely for over a year. [9] [12] She was also critical of the method used to validate the saliva test conducted by Asia Pacific Healthcare Group (APHG) in New Zealand, saying that APHG was using methods that were not widely used overseas. [13] [12] In September 2021, Wyllie said in an interview on Radio New Zealand that the New Zealand government had been "badly advised" with respect to saliva testing. [14] In response, Anoop Singh, the chief executive of APHG, questioned Wyllie's qualifications and the relevance of her research, and claimed that saliva samples could be tested in the same way as nasopharyngeal swabs (i.e. with RNA extraction). [1] Singh was reported as saying, "Sorry who is Anne Wyllie? Who is Anne Wyllie? She's a research scientist sitting in the US on some university campus. How is she qualified?" [15] Singh's comments led to a social media backlash, including the creation of Wyllie's English Wikipedia page. [15]

APHG was contracted by the New Zealand Ministry of Health to deliver saliva testing beginning in May 2021, but the programme did not begin until August. Singh blamed the delay between contracting and roll-out on the Ministry of Health. [1] [16]

Wyllie represented the Yale School of Public Health at the September 2021 Global COVID-⁠19 Summit hosted by president Joe Biden. [17] [18]

Honours and awards

Wyllie received a Medal of Excellence from the Northcote College Board of Trustees in 2020. She also received the COVID-19 Research Award from the Yale School of Public Health in 2021. [7]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Pneumonia</span> Inflammation of the alveoli of the lungs

Pneumonia is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli. Symptoms typically include some combination of productive or dry cough, chest pain, fever, and difficulty breathing. The severity of the condition is variable.

<span class="mw-page-title-main">Sputum</span> Mucus that is coughed up from the lower airways

Sputum is mucus that is coughed up from the lower airways. In medicine, sputum samples are usually used for a naked eye examination, microbiological investigation of respiratory infections and cytological investigations of respiratory systems. It is crucial that the specimen does not include any mucoid material from the nose or oral cavity.

<i>Streptococcus pneumoniae</i> Species of bacterium

Streptococcus pneumoniae, or pneumococcus, is a Gram-positive, spherical bacteria, alpha-hemolytic member of the genus Streptococcus. They are usually found in pairs (diplococci) and do not form spores and are non motile. As a significant human pathogenic bacterium S. pneumoniae was recognized as a major cause of pneumonia in the late 19th century, and is the subject of many humoral immunity studies.

<span class="mw-page-title-main">Lower respiratory tract infection</span> Medical term

Lower respiratory tract infection (LRTI) is a term often used as a synonym for pneumonia but can also be applied to other types of infection including lung abscess and acute bronchitis. Symptoms include shortness of breath, weakness, fever, coughing and fatigue. A routine chest X-ray is not always necessary for people who have symptoms of a lower respiratory tract infection.

<span class="mw-page-title-main">Bacterial capsule</span> Polysaccharide layer that lies outside the cell envelope in many bacteria

The bacterial capsule is a large structure common to many bacteria. It is a polysaccharide layer that lies outside the cell envelope, and is thus deemed part of the outer envelope of a bacterial cell. It is a well-organized layer, not easily washed off, and it can be the cause of various diseases.

Pneumococcal pneumonia is a type of bacterial pneumonia that is caused by Streptococcus pneumoniae (pneumococcus). It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900,000 annually, with almost 400,000 cases hospitalized and fatalities accounting for 5-7% of these cases.

Pneumococcal infection is an infection caused by the bacterium Streptococcus pneumoniae.

<span class="mw-page-title-main">Pneumolysin</span>

Pneumolysin is a virulence factor of the Gram-positive bacteria Streptococcus pneumoniae.

<span class="mw-page-title-main">Austrian syndrome</span> Medical condition

Austrian syndrome, also known as Osler's triad, is a medical condition that was named after Robert Austrian in 1957. The presentation of the condition consists of pneumonia, endocarditis, and meningitis, all caused by Streptococcus pneumoniae. It is associated with alcoholism due to hyposplenism and can be seen in males between the ages of 40 and 60 years old. Robert Austrian was not the first one to describe the condition, but Richard Heschl or William Osler were not able to link the signs to the bacteria because microbiology was not yet developed.

Streptococcus pseudopneumoniae is a gram-positive coccus that may cause pneumonia in humans. It was first described in 2004. The organism is often mistaken for S. pneumoniae and its clinical importance is as yet uncertain. It seems likely that most cases of S. pseudopneumoniae pneumonia are misdiagnosed as S. pneumoniae.

<span class="mw-page-title-main">Nasopharyngeal swab</span>

A nasopharyngeal swab is a device used for collecting a sample of nasal secretions from the back of the nose and throat. The sample is then analyzed for the presence of organisms or other clinical markers for disease. This diagnostic method is commonly used in suspected cases of whooping cough, diphtheria, influenza, and various types of diseases caused by the coronavirus family of viruses, including SARS, MERS, and COVID-19.

Candidatus Ornithobacterium hominis is a gram-negative bacterial species that colonises the human respiratory tract. Despite being related to the bird pathogen O. rhinotracheale, it is not a zoonosis. It has been detected in microbiome data from people around the world, including The Gambia, Madagascar and Central African Republic, Kenya, Mae La refugee camp in Thailand, rural Venezuela, Australia, and Fiji.

<span class="mw-page-title-main">COVID-19 testing</span> Diagnostic testing for SARS-CoV-2 virus infection

COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2. The two main types of tests detect either the presence of the virus or antibodies produced in response to infection. Molecular tests for viral presence through its molecular components are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.

Liise-anne Pirofski is a Professor of Medicine, Microbiology and Immunology at Albert Einstein College of Medicine and Montefiore Medical Center. She is a Member of the Association of American Physicians, and a Fellow of the American Association for the Advancement of Science, American Academy of Microbiology, American College of Physicians and the Infectious Diseases Society of America.

Necrotizing pneumonia (NP), also known as cavitary pneumonia or cavitatory necrosis, is a rare but severe complication of lung parenchymal infection. In necrotizing pneumonia, there is a substantial liquefaction following death of the lung tissue, which may lead to gangrene formation in the lung. In most cases patients with NP have fever, cough and bad breath, and those with more indolent infections have weight loss. Often patients clinically present with acute respiratory failure. The most common pathogens responsible for NP are Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae. Diagnosis is usually done by chest imaging, e.g. chest X-ray, CT scan. Among these CT scan is the most sensitive test which shows loss of lung architecture and multiple small thin walled cavities. Often cultures from bronchoalveolar lavage and blood may be done for identification of the causative organism(s). It is primarily managed by supportive care along with appropriate antibiotics. However, if patient develops severe complications like sepsis or fails to medical therapy, surgical resection is a reasonable option for saving life.

Debby Bogaert is a Dutch physician who is Professor of Paediatric Infectious Diseases at the University of Edinburgh. Her research considers the physiology and pathophysiology of respiratory infections.

<span class="mw-page-title-main">Daniela M. Ferreira</span> Brazilian immunologist

Daniela M. Ferreira is a Brazilian British immunologist. She is a specialist in bacterial infection, respiratory co-infection, mucosal immunology and vaccine responses. She is currently Professor of Respiratory Infection and Vaccinology at the Oxford Vaccine Group in the Department of Paediatrics at the University of Oxford and the Director of the Liverpool Vaccine Group at the Liverpool School of Tropical Medicine. She leads a team of scientists studying protective immune responses against pneumococcus and other respiratory pathogens such as SARS-CoV2. Her team has established a novel method of inducing pneumococcal carriage in human volunteers. They use this model to:

<span class="mw-page-title-main">Ian Town</span> Chief Science Advisor to Ministry of Health, NZ

George Ian TownFRACP is a New Zealand respiratory scientist and health official. He was appointed the Chief Science Advisor to the New Zealand Ministry of Health in 2019.

<span class="mw-page-title-main">Competence stimulating peptide</span>

Competence stimulating peptide (CSP), a chemical messenger assisting quorum sensing initiation, exists in many bacterial genera. Bacterial transformation of deoxyribonucleic acids (DNA) is driven by CSP coupled quorum sensing.

References

  1. 1 2 3 "Chief executive of Government's chosen saliva testing provider lashes out at criticism". Stuff. 11 September 2021. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
  2. 1 2 "Kiwi 'spit queen' created a Covid-19 saliva test". Stuff. 17 September 2021. Archived from the original on 13 October 2021. Retrieved 16 October 2021.
  3. "36151715591113780816". viaf.org. Retrieved 16 October 2021.
  4. "Saliva – a game changer for Covid-19 testing - The University of Auckland". www.auckland.ac.nz. Retrieved 25 October 2021.
  5. Wyllie, Anne Louise (2009). In vitro studies of the anti-tumour agent DMXAA (Thesis). The University of Auckland.
  6. 1 2 Wyllie, A. L. (22 September 2016). "Molecular surveillance of pneumococcal carriage in all ages". Utrecht University Repository. hdl:1874/341331. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
  7. 1 2 3 "Anne Wyllie, PhD". ysph.yale.edu. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
  8. Anne L Wyllie; Mei Ling J N Chu; Mariëlle H B Schellens; et al. (11 July 2014). "Streptococcus pneumoniae in saliva of Dutch primary school children". PLOS One . 9 (7): e102045. Bibcode:2014PLoSO...9j2045W. doi: 10.1371/JOURNAL.PONE.0102045 . ISSN   1932-6203. PMC   4094488 . PMID   25013895. Wikidata   Q33889880.
  9. 1 2 "Saliva testing ramping up, but has NZ been too slow?". www.rnz.co.nz. 7 September 2021. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
  10. 1 2 3 "The Spit Queen, The Economist and the NBA". The Indicator from Planet Money. NPR. Archived from the original on 9 September 2021. Retrieved 12 September 2021.
  11. 1 2 Anne L Wyllie; John Fournier; Arnau Casanovas-Massana; et al. (28 August 2020). "Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2". The New England Journal of Medicine . doi:10.1056/NEJMC2016359. ISSN   0028-4793. PMID   32857487. Wikidata   Q98781368.
  12. 1 2 "Slow saliva testing roll-out hurting New Zealand's ability to get on top of outbreak: Scientist". Stuff. 23 August 2021. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
  13. "'Fumbling over saliva testing': Expert scientist questions whether Jacinda Ardern has been misinformed". NZ Herald. Archived from the original on 11 September 2021. Retrieved 12 September 2021.
  14. "Live Covid-19 updates: Government criticised over saliva testing 'misinformation'". RNZ. 7 September 2021. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
  15. 1 2 Foneska, Dileepa (24 September 2021). "Covid-19: U-turn on saliva testing as fears grow around nasal swab hesitancy". Stuff. Archived from the original on 5 October 2021. Retrieved 5 October 2021.
  16. Manhire, Toby (12 September 2021). "Live updates, September 12: New mystery cases at Middlemore ahead of cabinet alert level decision". The Spinoff. Archived from the original on 12 September 2021. Retrieved 12 September 2021.
  17. "President Biden Invites Yale School of Public Health Scientist to Participate in COVID-19 Global Summit Hosted by United Nations" (Press release). New Haven, Connecticut: Yale School of Public Health. 22 September 2021. Retrieved 19 October 2021.
  18. "Global COVID-⁠19 Summit: Ending the Pandemic and Building Back Better". Whitehouse. 24 September 2021. Retrieved 18 October 2021.